Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. GLP-1 receptor agonists like Ozempic (semaglutide) are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!